Effects of exercise training on asthma-related genetic changes
Examining the Effect of Exercise Training on LncRNA MALAT1 Expression in Asthma Patients
This study is testing whether a special exercise program that strengthens breathing muscles can help people with severe asthma feel better and improve their quality of life while also looking at any genetic changes that happen.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Saglik Bilimleri Universitesi Academic / other |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT06776315 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how traditional respiratory rehabilitation combined with respiratory muscle strengthening training affects asthmatic patients at a genetic level. It aims to determine if this combined approach improves rehabilitation outcomes such as exercise capacity, shortness of breath, and muscle strength, while also assessing its impact on quality of life and psychological well-being. The study will include participants diagnosed with severe persistent asthma and will evaluate genetic changes associated with the interventions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 diagnosed with severe persistent asthma and exhibiting specific type 2 inflammation markers.
Not a fit: Patients with recent respiratory infections, significant smoking history, or certain comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance rehabilitation outcomes and overall quality of life for patients with asthma.
How similar studies have performed: While exercise training has shown benefits in asthma management, this specific approach examining genetic changes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Being between the ages of 18 and 75, * Being diagnosed with severe persistent asthma by a chest physician in accordance with the Global Initiative for Asthma (GINA) guideline criteria, * Patients with type 2 inflammation markers. According to the accepted standard; Peripheral eosinophils ≥150/µL and/or induced sputum eosinophils ≥2% - Airway hyperresponsiveness (PC20 methacholine \< 8 mg/mL) and/or bronchodilator response (\>12% or 200 mL improvement in % predicted FEV1 following 400 mg salbutamol inhalation) Exclusion Criteria: * Having had a recent (within the last month) respiratory tract infection, * Having a smoking history of over 10 packs/years or having a smoking history within 6 months of quitting smoking, * Having received oral corticosteroid treatment within the last 4 weeks, * Having a Body Mass Index \>30, * Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Allergic Bronchopulmonary Aspergillosis (ABPA), * Vasculitis, * History of malignancy, * Pregnancy, * Presence of a musculoskeletal, neurological or cardiac disease that would prevent exercise.
Where this trial is running
Istanbul
- University of Health Sciences — Istanbul, Turkey (Recruiting)
Study contacts
- Principal investigator: Fulya Senem KARAAHMETOGLU, PhD (c) — Saglik Bilimleri Universitesi
- Study coordinator: Fulya Senem KARAAHMETOGLU
- Email: fulyakaraahmet@gmail.com
- Phone: +90 216 346 36 36
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.